Punita Lal Joins Lupin Board as Additional Director

She has held senior positions at Coca-Cola in China and PepsiCo in India

Lupin receives USFDA approval for Rivaroxaban Tablets

Alembic Pharmaceuticals receives USFDA final approval for Rivaroxaban Tablets USP

Abbott India posts Q4 FY25 net profit at Rs. 367.04 Cr

The company has posted net profit of Rs. 1,414.44 crores for the Financial Year ended March 31, 2025

Wanbury posts Q4 FY25 consolidated PAT at Rs. 20.25 Cr

The company has posted net profit of Rs. 30.53 crores for the Financial Year ended March 31, 2025

Solara Active Pharma Sciences posts Q4 FY25 consolidated loss at Rs. 2.10 Cr

The company has posted net profit of Rs. 0.54 crores for the Financial Year ended March 31, 2025

Neuland Laboratories posts Q4 FY25 consolidated PAT at Rs. 27.80 Cr

The company has posted net profit of Rs. 260.10 crores for the Financial Year ended March 31, 2025

Jubilant Pharmova posts Q4 FY25 consolidated PAT at Rs. 153.6 Cr

Jubilant Pharmova has posted net profit of Rs. 839.4 crores for the Financial Year ended March 31, 2025

Shelter Pharma launches three new products

Shelter Pharma Limited is set to capitalize on the growing demand for natural health products in India

Lupin posts consolidated Q4 FY25 PAT at Rs. 772.52 Cr